Expert on Japan Retail and Consumer Markets, JapanConsuming

Michael Causton

Expert on Japan Retail and Consumer Markets

Real Insight on Japanese Consumer Markets

JapanConsuming

JapanConsuming is a specialist research firm producing intelligence on Japanese retail and consumer markets. Founded in 2000, JapanConsuming has become the leading provider of insights on Japanese retailers and consumer trends to retailers, brands, government agencies and investors. As well as a highly regarded monthly report on the market, JapanConsuming produces in-depth reports on retail sectors, seminars on key trends and telephone consulting to investors on trends and retailers.

JapanConsuming was founded by Michael Causton and Roy Larke. 

Event-Driven

The Japanese drugstore sector has been consolidating fast for a decade led by <a href="https://www.smartkarma.com/entities/aeon-co-ltd" target="_blank" data-smartkarma-citation="entities:3:1">Aeon's (8267 JP)</a> Welcia subsidiary, <a href="https://www.smartkarma.com/entities/tsuruha-holdings-inc" target="_blank" data-smartkarma-citation="entities:9536:1">Tsuruha Holdings (3391 JP)</a> and <a href="https://www.smartkarma.com/entities/sundrug-co-ltd" target="_blank" data-smartkarma-citation="entities:12615:1">Sundrug Co Ltd (9989 JP)</a>, which have taken the top three spots in the sector ahead of the long-time leader, <a href="https://www.smartkarma.com/entities/matsumotokiyoshi-holdings-co" target="_blank" data-smartkarma-citation="entities:2259:1">Matsumotokiyoshi Holdings Co (3088 JP)</a>.
Last month the latter tried to retake its pole position by opening negotiations to buy seventh-ranked <a href="https://www.smartkarma.com/entities/cocokara-fine-inc" target="_blank" data-smartkarma-citation="entities:15447:1">Cocokara Fine (3098 JP)</a>. A few days later, however, sixth-ranked <a href="https://www.smartkarma.com/entities/sugi-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:9255:1">Sugi Holdings (7649 JP)</a> began its own negotiations, creating an unusual situation where two companies are publicly bidding for the same target.
(For details on the deal and the likely implications for respective share prices etc, as always I defer to <a href="https://www.smartkarma.com/profiles/travis-lundy" target="_blank" data-smartkarma-citation="accounts:25">Travis Lundy</a> who has an excellent analysis on this in his Insight <a href="https://www.smartkarma.com/insights/cocokara-fine-cocokara" target="_blank">here</a>).
A deal with Cocokara Fine is crucial for Matsumotokiyoshi. If it succeeds, it will again lead the sector with a business a third bigger than the current leader. If it fails to woo the smaller firm and Sugi succeeds, however, Matsumotokiyoshi will have fallen from sector leader to the sixth position in three years and will likely want to start wooing current third-ranked player <a href="https://www.smartkarma.com/entities/sundrug-co-ltd" target="_blank" data-smartkarma-citation="entities:12615:1">Sundrug Co Ltd (9989 JP)</a>. It may even try and negotiate a partial merger with Tsuruha if it doesn't want to be left behind in what will likely become a sector dominated by three or four major retail groups in the next five years.
Whatever the outcome of the Cocokara Fine deal, further consolidation will occur in Japan's drugstore sector and M&amp;A will be a key strategy to make this happen.

The Japanese drugstore sector has been consolidating fast for a decade led by Aeon's (8267 JP) Welcia subsidiary, Tsuruha Holdings (3391 JP) and Sundrug Co Ltd (9989 JP), which have taken the top three spots in the sector ahead of the long-time leader, Matsumotokiyoshi Holdings Co (3088 JP).
Last month the latter tried to retake its pole position by opening negotiations to buy seventh-ranked Cocokara Fine (3098 JP). A few days later, however, sixth-ranked Sugi Holdings (7649 JP) began its own negotiations, creating an unusual situation where two companies are publicly bidding for the same target.
(For details on the deal and the likely implications for respective share prices etc, as always I defer to Travis Lundy who has an excellent analysis on this in his Insight here).
A deal with Cocokara Fine is crucial for Matsumotokiyoshi. If it succeeds, it will again lead the sector with a business a third bigger than the current leader. If it fails to woo the smaller firm and Sugi succeeds, however, Matsumotokiyoshi will have fallen from sector leader to the sixth position in three years and will likely want to start wooing current third-ranked player Sundrug Co Ltd (9989 JP). It may even try and negotiate a partial merger with Tsuruha if it doesn't want to be left behind in what will likely become a sector dominated by three or four major retail groups in the next five years.
Whatever the outcome of the Cocokara Fine deal, further consolidation will occur in Japan's drugstore sector and M&amp;A will be a key strategy to make this happen.

Drug-Fuelled Marriages and Macho Shachos* in Japan

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Five weeks ago at the end of April just before Golden Week, specialty drugstore retailers <a href="https://www.smartkarma.com/entities/cocokara-fine-inc" target="_blank" data-smartkarma-citation="entities:15447:1">Cocokara Fine (3098 JP)</a> (#7 in sales) and <a href="https://www.smartkarma.com/entities/matsumotokiyoshi-holdings-co" target="_blank" data-smartkarma-citation="entities:2259:1">Matsumotokiyoshi Holdings Co (3088 JP)</a> (#4 or #5 in sales) announced the start of talks aimed at the possible merger of drugstore operations to become the largest drugstore operator in Japan with pro-forma net revenues of ~¥975bn annually (beating leader <a href="https://www.smartkarma.com/entities/welcia-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:20895:1">Welcia Holdings (3141 JP)</a>'s ¥780bn, with an eventual capital merger possible. Talks were set to conclude by September.<a href="https://www.smartkarma.com/profiles/michael-causton" target="_blank" data-smartkarma-citation="accounts:2415">Michael Causton</a>, as is his wont, wrote about the possible tie-up a couple of weeks ago in <a href="https://www.smartkarma.com/insights/matsukiyo-and-cocokara-fine-tie-to-shake-up-drugstore-sector" target="_blank" data-smartkarma-citation="insights:29890">Matsukiyo and Cocokara Fine Tie to Shake up Drugstore Sector</a>. It is worth a read. For a long time, the drugstore sector was the darling of foreign investors because of decent top line growth but post-GFC the industry slowed down for several years before jumping in Fiscal Years 2016 and 2017 (ending in early 2018 in most cases) but he thinks the sector still has growth (see <a href="https://www.smartkarma.com/insights/japan-drugstores-set-to-expand-further" target="_blank" data-smartkarma-citation="insights:28119">Japan Drugstores Set to Expand Further</a>).  His conclusion? <blockquote>Drugstore retailing today is unrecognisable compared to 10 years ago and the speed of change and development is now set to accelerate even further, with M&amp;A a key strategy.</blockquote><h2>The New News</h2>Over the weekend, Sector #6 <a href="https://www.smartkarma.com/entities/sugi-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:9255:1">Sugi Holdings (7649 JP)</a> announced that it had agreed to enter business integration talks with Cocokara Fine over the weekend with the aim to conclude talks by the end of July - at least a month ahead of when the talks between Matsukiyo and Cocokara were scheduled to end. It turns out the announcement between Matsukiyo and Cocokara turned some heads in the industry and Sugi Holdings approached Cocokara just a couple of days later. Interestingly - and highly unusual for Japan - Matsukiyo <a href="https://www.matsumotokiyoshi-hd.co.jp/news/data/7aab7e719783f4e1f894dee904e74820.pdf" target="_blank">said</a> (Japanese-only) today that it was going to continue to negotiate. This makes it a situation where there are two strategic acquirors for one asset (Cocokara) and they are both "friendly." This is practically unheard of in Japan. This sets up a competitive bidding situation for Cocokara which is worthwhile thinking about.<hr><div class="content-remarks">*With apologies to non-Japanese readers, the title is a pun playing on the origins of the company name and the English and Japanese treatment of "fine" and good.</div>

Five weeks ago at the end of April just before Golden Week, specialty drugstore retailers Cocokara Fine (3098 JP) (#7 in sales) and Matsumotokiyoshi Holdings Co (3088 JP) (#4 or #5 in sales) announced the start of talks aimed at the possible merger of drugstore operations to become the largest drugstore operator in Japan with pro-forma net revenues of ~¥975bn annually (beating leader Welcia Holdings (3141 JP)'s ¥780bn, with an eventual capital merger possible. Talks were set to conclude by September.Michael Causton, as is his wont, wrote about the possible tie-up a couple of weeks ago in Matsukiyo and Cocokara Fine Tie to Shake up Drugstore Sector. It is worth a read. For a long time, the drugstore sector was the darling of foreign investors because of decent top line growth but post-GFC the industry slowed down for several years before jumping in Fiscal Years 2016 and 2017 (ending in early 2018 in most cases) but he thinks the sector still has growth (see Japan Drugstores Set to Expand Further).  His conclusion? Drugstore retailing today is unrecognisable compared to 10 years ago and the speed of change and development is now set to accelerate even further, with M&amp;A a key strategy.The New NewsOver the weekend, Sector #6 Sugi Holdings (7649 JP) announced that it had agreed to enter business integration talks with Cocokara Fine over the weekend with the aim to conclude talks by the end of July - at least a month ahead of when the talks between Matsukiyo and Cocokara were scheduled to end. It turns out the announcement between Matsukiyo and Cocokara turned some heads in the industry and Sugi Holdings approached Cocokara just a couple of days later. Interestingly - and highly unusual for Japan - Matsukiyo said (Japanese-only) today that it was going to continue to negotiate. This makes it a situation where there are two strategic acquirors for one asset (Cocokara) and they are both "friendly." This is practically unheard of in Japan. This sets up a competitive bidding situation for Cocokara which is worthwhile thinking about.*With apologies to non-Japanese readers, the title is a pun playing on the origins of the company name and the English and Japanese treatment of "fine" and good.

Equity Bottom-Up

Two of the country’s largest mass market drugstore operators announced talks about a new tie-up last month. If it happens, <a href="https://www.smartkarma.com/entities/2259" target="_blank" data-smartkarma-citation="entities:2259:1">Matsumotokiyoshi Holdings Co (3088 JP)</a> and <a href="https://www.smartkarma.com/entities/15447" target="_blank" data-smartkarma-citation="entities:15447:1">Cocokara Fine (3098 JP)</a> will jointly run a drugstore operation more than a third larger than any current rival.
In this fast developing sector, such a move will not be taken lying down by rivals and could well stimulate a rush of similar tie-ups over the next year.

Two of the country’s largest mass market drugstore operators announced talks about a new tie-up last month. If it happens, Matsumotokiyoshi Holdings Co (3088 JP) and Cocokara Fine (3098 JP) will jointly run a drugstore operation more than a third larger than any current rival.
In this fast developing sector, such a move will not be taken lying down by rivals and could well stimulate a rush of similar tie-ups over the next year.

Matsukiyo and Cocokara Fine Tie to Shake up Drugstore Sector

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

ja research

ja research is an independent research platform focused exclusively on Japanese equities. Leveraging data and graphic analysis provided by Japan Analytics, we provide insights on small and medium-sized companies that have been ignored by the sell-side as well as challenging conventional wisdom on larger companies. We also offer analyst and corporate access, the latter with translation if required. 

Quantitative Analysis

- MARKET COMPOSITE -<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/081/436/original/2019-03-10_11-07-01.png?1552183736" class="editor-image img-responsive" data-smartkarma-image-id="81436"></figure><div style="text-align: center;" class="content-caption">Source: Japan Analytics</div><div>
SOUTHBOUND - The upside we anticipated two weeks ago turned out to be only ¥6t before the harsh realities of some weak macro data intervened and sent the market 3% lower over the last two trading days suggesting the bear market rally is now over. After peaking at 48%, the market-value-based percentage above the weighted sum of moving averages has now retreated to 33%. </div><hr>- SECTORS - <figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/081/437/original/2019-03-10_11-38-43.png?1552185548" class="editor-image img-responsive" data-smartkarma-image-id="81437"></figure><div style="text-align: left;" class="content-caption">
LEGEND: The 'sparklines' show the three-year trend in the weighted percentage above moving average relative to the Market Composite and the 'STDev' column is a measure of the variability of that relative measure. The table also provides averages for the breaks above and breaks below and the positive and negative crossovers.</div>SECTOR BREAKDOWN - The top six sectors remain domestic and defensive and are unchanged from two weeks ago with REITs, the clear leader. Equally predictable is the bottom half-dozen - Banks, Non-Bank Finance, Retail, Autos, and Metals remain from two weeks ago, with Machinery replacing Construction. Banks stay at the bottom, and the sector had its largest volume 'day' as measured by our Volume Score since September 21st, 2018 on Friday although many other sectors were 'active.' <figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/081/440/original/2019-03-10_11-54-26.png?1552186476" class="editor-image img-responsive" data-smartkarma-image-id="81440"></figure><div class="content-caption">Source: Japan Analytics</div><hr>- COMPANIES -COMPANY MOVING AVERAGE OUTLIERS - As with the Market Composite and Sectors, the Moving Average Outlier indicator uses a weighted sum of each company's share price relative to its 5-day, 20-day, 60-day, 120-day and 240-day moving averages. 'Extreme' values are weighted sums greater than 100% and less than -100%. We would caution that this indicator is best used for timing shorter-term reversals and, in many cases, higher highs and lower lows will be seen. <div class="content-highlight">
In the DETAIL section below, we highlight the current top and bottom twenty-five large capitalisation outliers, as well as those companies that have seen the most significant positive and negative changes in their outlier percentage in the last two weeks and provide short comments on companies of particular note.
Our most extreme positive outlier two weeks ago, <a href="https://www.smartkarma.com/entities/26181" target="_blank" data-smartkarma-citation="entities:26181:1">Pksha Technology (3993 JP)</a> declined by 8% and 'tops' our most negative two-week change list, while the most negative outlier <a href="https://www.smartkarma.com/entities/24540" target="_blank" data-smartkarma-citation="entities:24540:1">SanBio (4592 JP)</a> rose by 3%. <a href="https://www.smartkarma.com/entities/8244" target="_blank" data-smartkarma-citation="entities:8244:1">Leopalace21 (8848 JP)</a> which was also featured recovered by 9%.
<a href="https://www.smartkarma.com/entities/2709" target="_blank" data-smartkarma-citation="entities:2709:1">AnGes (4563 JP)</a> is currently the most extreme large cap positive outlier having peaked at '492' on 26th February up from a 'trough' of -132 in December. Biotechnology peer <a href="https://www.smartkarma.com/entities/24540" target="_blank" data-smartkarma-citation="entities:24540:1">SanBio (4592 JP)</a> is, for the third time this year, the most extreme negative outlier, having topped the 13th January and 24th February positive outlier lists and is another 'round-tripper'. 
</div><div class="content-caption">
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/081/441/original/2019-03-10_12-13-00.png?1552187591" class="editor-image img-responsive" data-smartkarma-image-id="81441"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/081/442/original/2019-03-10_12-17-48.png?1552187878" class="editor-image img-responsive" data-smartkarma-image-id="81442"></figure>Source: Japan Analytics
</div>

- MARKET COMPOSITE -Source: Japan Analytics
SOUTHBOUND - The upside we anticipated two weeks ago turned out to be only ¥6t before the harsh realities of some weak macro data intervened and sent the market 3% lower over the last two trading days suggesting the bear market rally is now over. After peaking at 48%, the market-value-based percentage above the weighted sum of moving averages has now retreated to 33%. - SECTORS - 
LEGEND: The 'sparklines' show the three-year trend in the weighted percentage above moving average relative to the Market Composite and the 'STDev' column is a measure of the variability of that relative measure. The table also provides averages for the breaks above and breaks below and the positive and negative crossovers.SECTOR BREAKDOWN - The top six sectors remain domestic and defensive and are unchanged from two weeks ago with REITs, the clear leader. Equally predictable is the bottom half-dozen - Banks, Non-Bank Finance, Retail, Autos, and Metals remain from two weeks ago, with Machinery replacing Construction. Banks stay at the bottom, and the sector had its largest volume 'day' as measured by our Volume Score since September 21st, 2018 on Friday although many other sectors were 'active.' Source: Japan Analytics- COMPANIES -COMPANY MOVING AVERAGE OUTLIERS - As with the Market Composite and Sectors, the Moving Average Outlier indicator uses a weighted sum of each company's share price relative to its 5-day, 20-day, 60-day, 120-day and 240-day moving averages. 'Extreme' values are weighted sums greater than 100% and less than -100%. We would caution that this indicator is best used for timing shorter-term reversals and, in many cases, higher highs and lower lows will be seen. 
In the DETAIL section below, we highlight the current top and bottom twenty-five large capitalisation outliers, as well as those companies that have seen the most significant positive and negative changes in their outlier percentage in the last two weeks and provide short comments on companies of particular note.
Our most extreme positive outlier two weeks ago, Pksha Technology (3993 JP) declined by 8% and 'tops' our most negative two-week change list, while the most negative outlier SanBio (4592 JP) rose by 3%. Leopalace21 (8848 JP) which was also featured recovered by 9%.
AnGes (4563 JP) is currently the most extreme large cap positive outlier having peaked at '492' on 26th February up from a 'trough' of -132 in December. Biotechnology peer SanBio (4592 JP) is, for the third time this year, the most extreme negative outlier, having topped the 13th January and 24th February positive outlier lists and is another 'round-tripper'. 

Source: Japan Analytics


🇯🇵 Japan: Moving Average Outliers - AnGes, SanBio, Adastria, AIN, Sumco & Benefit One

<div class="content-caption">
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/080/230/original/2019-02-26_16-49-25.png?1551182690" class="editor-image img-responsive" data-smartkarma-image-id="80230"></figure>
Source: Japan Analytics
</div>
LARGE CAP RESULTS &amp; REVISION SCORES - The final instalment of our series of reviews of Japan's most recent earnings and revisions announcements covers the Results &amp; Revision Scores for Japan's 785 larger capitalisation companies with a market capitalisation of over ¥100b.
In the DETAIL section below we look at:- 
<ul>
<li>The 30 top and bottom-ranked companies by Results &amp; Revision Score as well as the top and bottom thirty ranked by change in score over the last quarter and provide brief comments on companies and topics of note.</li>
<li>By comparing Results Scores and Forecast/Revision Scores, we sort companies into'Optimists', 'Pessimists', 'Increasingly Optimistic' and 'Increasingly Pessimistic' categories.</li>
<li>As shown above, the relationship between the Results &amp; Revision Score (RRS) and our Relative Price Score (RPS) for each company and divide the large-cap universe into four 'quadrants' - 'Contrarian Buy' (Low RRS &amp; Low RPS) , 'Contrarian Sell' (High RRS &amp; High RPS), 'Peak Growth' (High RRS &amp; Low RPS) and 'Ex-Growth/Turnaround'  (Low RRS &amp; High RPS), highlighting the outliers in each quadrant.
<ul>
<li>In the two 'Contrarian' quadrants, the market is aligned with the current earnings momentum of the companies suggesting opportunities exist only for those willing or brave enough to take a contrarian view. </li>
<li>For 'Peak Growth', the market is calling for a downturn in momentum that has yet to be reflected in quarterly earnings. Where the cycle is more prolonged than expected, there are often opportunities for short-term rebounds in what are normally relatively-inexpensive companies.</li>
<li>The 'Ex-Growth' quadrant often consists of former 'Contrarian Sell's where the market is reluctant to acknowledge that the cycle has turned. This quadrant can also contain 'Turnarounds' - formerly 'Contrarian Buys' where the market is correctly anticipating a change in fortunes.   </li>
</ul>
</li>
<li>Finally, we provide tables of the top and bottom five ranked companies in each of our 30 Sectors.</li>
</ul>



Source: Japan Analytics

LARGE CAP RESULTS &amp; REVISION SCORES - The final instalment of our series of reviews of Japan's most recent earnings and revisions announcements covers the Results &amp; Revision Scores for Japan's 785 larger capitalisation companies with a market capitalisation of over ¥100b.
In the DETAIL section below we look at:- 

The 30 top and bottom-ranked companies by Results &amp; Revision Score as well as the top and bottom thirty ranked by change in score over the last quarter and provide brief comments on companies and topics of note.
By comparing Results Scores and Forecast/Revision Scores, we sort companies into'Optimists', 'Pessimists', 'Increasingly Optimistic' and 'Increasingly Pessimistic' categories.
As shown above, the relationship between the Results &amp; Revision Score (RRS) and our Relative Price Score (RPS) for each company and divide the large-cap universe into four 'quadrants' - 'Contrarian Buy' (Low RRS &amp; Low RPS) , 'Contrarian Sell' (High RRS &amp; High RPS), 'Peak Growth' (High RRS &amp; Low RPS) and 'Ex-Growth/Turnaround'  (Low RRS &amp; High RPS), highlighting the outliers in each quadrant.

In the two 'Contrarian' quadrants, the market is aligned with the current earnings momentum of the companies suggesting opportunities exist only for those willing or brave enough to take a contrarian view. 
For 'Peak Growth', the market is calling for a downturn in momentum that has yet to be reflected in quarterly earnings. Where the cycle is more prolonged than expected, there are often opportunities for short-term rebounds in what are normally relatively-inexpensive companies.
The 'Ex-Growth' quadrant often consists of former 'Contrarian Sell's where the market is reluctant to acknowledge that the cycle has turned. This quadrant can also contain 'Turnarounds' - formerly 'Contrarian Buys' where the market is correctly anticipating a change in fortunes.   


Finally, we provide tables of the top and bottom five ranked companies in each of our 30 Sectors.


🇯🇵 Japan • Winter Large Cap Results & Revision Scores - Contrarian Buys & Sells/​Peak & Ex-Growth

Japan

cocokara fine Inc. is a holding company established through a merger of SEIJO Corporation and Segami Medics. The Company operates drug chain stores which sell medicines, health food, cosmetics, nursery items and daily necessity goods.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cocokara Fine (3098 JP)

Drug-Fuelled Marriages and Macho Shachos* in Japan

The Japanese drugstore sector has been consolidating fast for a decade led by Aeon's (8267 JP) Welcia subsidiary, Tsuruha Holdings (3391 JP) and...

Michael Causton

Cocokara Fine は Cocokara いいね*

Five weeks ago at the end of April just before Golden Week, specialty drugstore retailers Cocokara Fine (3098 JP) (#7 in sales) and...

Travis Lundy

Matsukiyo and Cocokara Fine Tie to Shake up Drugstore Sector

Two of the country’s largest mass market drugstore operators announced talks about a new tie-up last month. If it happens, Matsumotokiyoshi...

Michael Causton

🇯🇵 Japan: Moving Average Outliers - AnGes, SanBio, Adastria, AIN, Sumco & Benefit One

- MARKET COMPOSITE - SOUTHBOUND - The upside we anticipated two weeks ago turned out to be only ¥6t before the harsh realities of some weak macro...

Campbell Gunn

🇯🇵 Japan • Winter Large Cap Results & Revision Scores - Contrarian Buys & Sells/Peak & Ex-Growth

LARGE CAP RESULTS & REVISION SCORES - The final instalment of our series of reviews of Japan's most recent earnings and revisions...

Campbell Gunn

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Drug-Fuelled Marriages and Macho Shachos* in Japan

The Japanese drugstore sector has been consolidating fast for a decade led by Aeon's (8267 JP) Welcia subsidiary, Tsuruha Holdings (3391 JP) and...

Michael Causton

Cocokara Fine は Cocokara いいね*

Five weeks ago at the end of April just before Golden Week, specialty drugstore retailers Cocokara Fine (3098 JP) (#7 in sales) and...

Travis Lundy

Matsukiyo and Cocokara Fine Tie to Shake up Drugstore Sector

Two of the country’s largest mass market drugstore operators announced talks about a new tie-up last month. If it happens, Matsumotokiyoshi...

Michael Causton

🇯🇵 Japan: Moving Average Outliers - AnGes, SanBio, Adastria, AIN, Sumco & Benefit One

- MARKET COMPOSITE - SOUTHBOUND - The upside we anticipated two weeks ago turned out to be only ¥6t before the harsh realities of some weak macro...

Campbell Gunn

🇯🇵 Japan • Winter Large Cap Results & Revision Scores - Contrarian Buys & Sells/​Peak & Ex-Growth

LARGE CAP RESULTS & REVISION SCORES - The final instalment of our series of reviews of Japan's most recent earnings and revisions...

Campbell Gunn

🇯🇵 Japan • Winter Large Cap Results & Revision Scores - Contrarian Buys & Sells/Peak & Ex-Growth